Module lead, Vaccinology
- Professor of Paediatric Infection and Immunity
Current research activities include clinical trials of new and improved vaccines for children and adults, surveillance of invasive bacterial diseases and pneumococcal vaccine impact in children in Nepal, studies of cellular and humoral immune responses to glycoconjugate and typhoid vaccines, and development of a serogroup B meningococcal vaccine.
He chaired the UK’s NICE meningitis guidelines development group, the NICE topic expert group developing quality standards for management of meningitis and meningococcal septicaemia. His research includes the design, development and clinical evaluation of vaccines including those for meningococcal disease and enteric fever and leads studies using a human challenge model of (para)typhoid. He runs surveillance for invasive bacterial diseases and studies the impact of pneumococcal vaccines in children in Nepal and leads a project on burden and transmission of typhoid in Nepal, Bangladesh and Malawi, and co-leads typhoid vaccine impact studies at these sites.
He chairs the UK Department of Health and Social Care’s Joint Committee on Vaccination and Immunisation, and is a member of WHO’s SAGE, and chaired the European Medicines Agency scientific advisory group on vaccines until 2020. He received the Bill Marshall award of the European Society for Paediatric Infectious Disease (ESPID) in 2013, the ESPID Distinguished Award for Education & Communication in 2015 and the Rosén von Rosenstein medal in 2019 awarded by the Swedish Paediatric Society and the Swedish Society of Medicine. He was elected to the Academy of Medical Sciences in 2016 and is an NIHR Senior Investigator. He made the first British ascent of Jaonli (6632m) in 1988 and Chamlang in 1991 (7309m) and was the Deputy leader of the successful 1994 British Medical Everest Expedition.
What time interval is needed between the administration of live attenuated vaccines?
Zimmermann P. et al, (2020), Archives of Disease in Childhood
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial (vol 396, pg 467, 2020)
Folegatti PM. et al, (2020), LANCET, 396, 466 - 466
Biomarkers for Disease Severity in Children Infected With Respiratory Syncytial Virus: A Systematic Literature Review.
Öner D. et al, (2020), The Journal of infectious diseases
Presumed Risk Factors and Biomarkers for Severe Respiratory Syncytial Virus Disease and Related Sequelae: Protocol for an Observational Multicenter, Case-Control Study From the Respiratory Syncytial Virus Consortium in Europe (RESCEU).
Jefferies K. et al, (2020), The Journal of infectious diseases
Respiratory Syncytial Virus Consortium in Europe (RESCEU) Birth Cohort Study: Defining the Burden of Infant Respiratory Syncytial Virus Disease in Europe.
Wildenbeest JG. et al, (2020), The Journal of infectious diseases